Yarrow Bioscience reports Q3 2026 net loss of $9.72 million
YARW•Yarrow Bioscience reported a third-quarter 2026 net loss of $9.72 million and cash of $268.86 million at September 30, which it expects to fund operations into 2030.
1. Quarterly results and cash
Yarrow Bioscience reported a third-quarter 2026 net loss of $9.72 million. Cash and cash equivalents more than doubled from December 31, 2025, to $268.86 million at September 30, 2026; the company expects the balance to fund operations into 2030, including completion of the DIRECTION-GD trial.
2. Trial enrollment
Enrollment continues in the Phase 2a portion of DIRECTION-GD, with topline results expected in the second half of 2027.
